Introduction
Sodium, potassium ATPases (Na,K-ATPases or sodium pumps) are biologically ubiquitous, membrane-bound enzyme complexes that combine ATP hydrolysis with the transport of cytoplasmic Na + out of the cell in exchange for extracellular K. 1 The enzymes help generate cationic gradients that are fundamental to a variety of cellular functions such as the regulation of cell volume and pH. Each Na,K-ATPase is composed primarily of one a-subunit and a smaller b-subunit which form the basic complex. 2 The a-subunit is responsible for most of the enzyme's ion pumping function. It contains amino acid motifs to bind sodium, potassium and ATP as well as binding sites for known enzyme inhibitors such as the cardiac glycoside ouabain. The b-subunit is involved in the routing of the a-b complex to the cell membrane and helps determine the kinetics of K + interaction. 3 In this work, we examine the Na,K-ATPase of the human parasitic platyhelminth, Schistosoma mansoni. Schistosomes are intravascular parasitic worms with complex life histories that infect .200 million people globally. Na,K-ATPase activity has been detected in extracts of S. mansoni adults 4 and a cDNA encoding a Na,K-ATPase a-subunit homolog, designated SNaK1a, has been isolated from an adult S. mansoni cDNA library. 5 This cDNA potentially encodes a protein of about 112 kDa possessing ten transmembrane regions as well as a phosphorylation site and an ATP binding domain, typical of members of the Na,K-ATPase a-subunit protein family. 5 Antibodies raised against an amino terminal peptide detect SNaK1a in membrane preparations of a variety of schistosome life cycle stages including eggs, cercariae and adult males and females, suggesting a general role for SNaK1a. 5 In adult worm sections, SNaK1a is detected in several tissues including muscle and nerve, and proteomic analysis detects the protein in the tegument (skin) of adults. 6 In this study, we clone a Na,K-ATPase b-subunit from S. mansoni, which we designate SNaK1b. Proteomic analysis has demonstrated that this protein, like SNaK1a, is found in the adult schistosome tegumental membranes 6 and a major research focus of our laboratory is the composition and function of the proteins in the tegument. 7 -10 In these membranes, the SNaK1a plus SNaK1b complex is likely host interactive, serving to generate and maintain a cationic gradient across the outer body surface. It has long been known that schistosomes maintain an electrical potential gradient across their tegument that is dominated by K + ions. 11 As schistosomula mature there is a change in the tegumental membrane potential. 12, 13 Concurrently the parasites become refractory to immune-mediated killing. 14, 15 This temporal correlation has led to the proposal that developmental changes in the tegument involving proteins like Na,K-ATPases are essential for the parasites to avoid immune elimination. 12 A more recent report suggests a direct role for Na,K-ATPases in conferring refractoriness to complement-mediated damage of schistosomula. 16 Because of this reported importance of Na,K-ATPases in immune defense and because of the prominence of proteins belonging to this protein family in overall cell metabolism, it seems likely that inhibiting schistosome Na,K-ATPases will constitute an effective anti-parasite therapy. To test this idea, and to better understand the complex role of Na,K-ATPases in the biology of schistosomes, we here clone a SNaK1b and monitor the effect of suppressing the SNaK1a and SNaK1b genes using RNAi on schistosomes in vitro and in vivo. Additionally, we monitor the impact of treating schistosome-infected mice with the Na,K-ATPase inhibitor, ouabain.
Materials and methods

Parasites and mice
The Puerto Rican strain of S. mansoni was used. Life cycle stages were obtained as described. 17 Parasite viability was assessed by Hoechst 33258 vital dye staining. 8 Work with female CD1 mice followed Tufts University IACUC approval.
Cloning SNaK1b
To clone SNaK1b, EST sequence information derived from proteomic analysis of tegumental membranes 6 was used to examine the S. mansoni genome database (version 3) which led to the identification of the presumptive SNaK1b gene. Next, using oligonucleotides designed from the first predicted exon (Beta1-2: 5'-ATGTCAATGCAGGAGTTCTCCGAT-3') and the 3'UTR downstream of the last predicted exon (Beta1-4: 5'-GCAATAATAATGAATA-GAGGCAT -3'), with adult parasite cDNA in a PCR, we amplified and then sequenced, at the Tufts University Core Facility, the complete predicted SNaK1b coding DNA (GenBank accession # EU784447).
Preparation and delivery of dsRNAs and post RNAi analysis
Small inhibitory RNAs (siRNAs), designed to target the SNaK1a and SNaK1b genes (Box 1), were delivered to schistosomula by electroporation. 9 Parasite size was measured by microscopic analysis, as outlined. 8 To monitor gene expression, quantitative real time PCR (qRT-PCR) was performed using custom TaqMan Assays with reagents listed in Box 1 and published conditions. 18 Western blot analysis was performed as in previous work. 18 
Infection of mice with siRNA-treated schistosomula
After RNAi treatment, one day old cultured schistosomula were either used to infect mice or were cultured, as described. 9 Mice were infected either immediately after RNAi treatment (day 0), and worms recovered 28 days later, or 4 days after RNAi treatment and worms recovered 42 days later. Recovered worms were examined and their SNaK1a and b gene expression levels were determined using qRT-PCR.
Delivery of siRNAs to infected mice hydrodynamically
At week six and seven after infection with 100 cercariae, mice (five per group) were injected via the tail vein with 50 mg control or SNaK1a plus SNaK1b siRNAs in 2.5 ml PBS using the hydrodynamic technique, as described. 19 One week later, worms were recovered, examined and their SNaK1 gene expression levels determined.
Box 1. Synthetic nucleic acids used in this study
Name
Target Sequence
SNaK1b 5'-GTCCCTCATTCGTTATTCTGCTGAC-3' Control None 5'-CTTCCTCTCTTTCTCTCCCTTGTGA-3' Primers and probes used for gene expression analysis using qRT- 
Treatment of infected mice with ouabain
One week after infecting mice with 200 cercariae, one group was injected intraperitoneally with 2.5 mg/kg ouabain (Sigma-Aldrich, MO) each week for 6 weeks. In the sixth week, mice received two injections, two days apart. At week seven post infection, worm burdens were determined. Liver egg measurements were performed as detailed. 17 
Statistical analysis
One-way ANOVA was used to compare median values among three or more groups. Student's t-tests were used to compare the means between a target and a control group.
Results
The SNaK1b cDNA and gene
The complete SNaK1b cDNA potentially encodes a 293 amino acid protein with a predicted relative molecular mass of 32 921 and pI of 7.87. Figure 1A shows an alignment of SNaK1b with diverse members of this protein family generated using ClustalW. Conserved motifs are highlighted. SNaK1b residues 1 -45 are intracellular with residues 46 -68 crossing the membrane (TM, Figure 1A ) and the remainder of the protein (residues 69 -293) being extracellular (http://www.cbs.dtu.dk/ services/TMHMM-2.0/). There are several highly conserved cysteine, proline and tyrosine residues. By analogy with other NaK-ATPase b subunits, cysteine residues in SNaK1b that are predicted to be disulfide linked are indicated in Figure 1A . 20 The SNaK1b protein has a single, non-conserved potential N-linked glycosylation site in the predicted extracellular domain ( 229 NFS 231 ). The protein displays 86% identity to its counterpart from Schistosoma japonicum (Sj) and exhibits about 30% identity when compared with either Drosophila melanogaster (Dm), Caenorhabditis elegans (Ce) or human (Hs) homologs. As illustrated in Figure 1B , the SNaK1b1gene is close to 24 kb in size and consists of six exons ranging in size from 70 bp (exon 5) to 292 bp (exon 3). The AT content of the exons varies from 52% (exon 1) to 69% (exon 5). All introns possesses canonical 'GT:AG' splice donor and acceptor sites. Examining the S. mansoni genome assembly 5 (http://www.sanger.ac.uk/resources/downloads/helminths/ schistosoma-mansoni.html) reveals that the SNaK1b gene is located on chromosome 1. gene expression is also highest in eggs but, unlike SNaK1a, its relative expression in miracidia, sporocysts and cercariae is low ( Figure 2B ). Both SNaK1 genes are expressed to a similar relative degree in the intravascular life stages (schistosomula and adult males and females), this level being about 40 -50% of the maximum seen in the egg stage.
Developmental expression profile of SNaK1a and SNaK1b
Suppression of SNaK1a and SNaK1b gene expression
The expression of both the SNaK1a and SNaK1b genes in schistosomula was suppressed in vitro by RNAi treatment. Figure 3A , left panel, shows robust suppression of SNaK1a (≥ 80%, p , 0.05) using two different siRNAs. Likewise, Figure 3A , right panel, shows substantial but lesser suppression of SNaK1b (about 40% suppression, p , 0.05). RNAi treatment targeting the SNaK1a gene also results in substantial suppression of SNaK1a protein production as determined by western analysis ( Figure 3B , upper panel, where the arrow indicates the position of migration of SNaK1a protein). No antibody against SNaK1b exists so we have not been able to examine SNaK1b-suppressed parasites for evidence of protein knock-down.
Parasite viability following gene suppression
Schistosomula cultured in vitro whose SNaK1a or SNaK1b gene was singly suppressed showed no significant difference in viability compared to controls ( Figure 4 ). In contrast, schistosomula in which both SNaK1a and SNaK1b were simultaneously suppressed ( Figure 4 , a1 + b1) exhibited significantly diminished viability -about half that of controls ( Figure 4 , none, p , 0.05).
RNAi treated and control worms were next used to infect mice. It was found that there was a substantial reduction in worm burden in the SNaK1-suppressed group compared to the control groups ( Figure 5A , p ¼ 0.03 SNaK1-suppressed versus None; p ¼ 0.07 SNaK1-suppressed group versus Control). Furthermore, the mean size of the parasites from the SNaK1a plus b suppressed group was significantly less than that of either of the control groups ( Figure 5B, p , 0.05) . Figure 6 shows SNaK1a (A) and SNaK1b (B) gene expression analysis in the suppressed versus control parasites. SNaK1a gene suppression was about 60% and SNaK1b gene suppression was about 40% at day 7 (white bars). These levels remain essentially unchanged in parasites maintained in culture until day 23 (grey bars), but increase somewhat in parasites recovered from infected mice at day 28 (black bars).
In three additional in vivo experiments, parasites were maintained in culture for four days before being used to infect mice; results are shown in Figure 7 . In each case, no (or very few) parasites whose SNaK1a and SNaK1b genes were targeted survived following infection. In contrast, many control parasites were recovered in each case.
Hydrodynamic delivery of siRNAs
Hydrodynamic delivery of siRNAs to schistosome infected mice did not measurably impact the worms in terms of numbers or in terms of SNaK1a/SNaK1b gene expression levels (data not shown). The following, similar numbers of worms (mean +SD), were recovered from these groups of mice: SNaK1 siRNA treated (22.8+8,5), control siRNA treated (19.8+5.6), and untreated (22.6+5.2).
Impact of ouabain treatment on parasite viability in vivo
No significant difference was detected in the number of worms or eggs recovered from mice treated with ouabain versus untreated controls ( Table 1 ). It remains possible that ouabain may impact egg viability but this was not measured in this work.
Discussion
Na,K-ATPase enzymes (also called sodium pumps) are ubiquitous plasma membrane bound, oligomeric enzymes consisting of two essential, non-covalently linked subunits. These are an a-subunit, which contains the binding sites for ATP, Na + and K + , and a b-subunit which is required for the proper membrane insertion of the a-subunit and for efficient ion exchange. 1 A schistosome Na,K-ATPase a homolog designated SNaK1a was previously cloned. 5 The 112 kDa SNaK1a protein was predicted to contain 10 transmembrane regions typical of this protein family as well as other conserved domains. 5 Here we described the cloning of a schistosome Na,K-ATPase b homolog which we designated SNaK1b. This 33 kDa protein has a single transmembrane domain and several highly conserved amino acid residues, including cysteines, prolines and tyrosines. b-Subunit isoforms have three conserved disulfide linkages within the extracellular domain 20, 21 and these exist in SNaK1b. 
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In other systems, these have been reported to stabilize the a-subunit, a/b interaction and functional activity of the holoenzyme. 22 Mutation of the P 244 residue in the Xenopus laevis b-subunit (conserved in SNaK1b) reduced by .90% the proper assembly and function of the Xenopus Na,K-ATPase complex, 23 highlighting the critical role proline plays in the proper folding of the b-subunit and its ability to associate efficiently with the a-subunit. Mutagenesis of two highly conserved tyrosines (equivalent to Y 48 and Y 52 in SNaK1b) perturb the transport kinetics of the Xenopus sodium pump in an additive way showing that these residues of the b-subunit can be determinants of intrinsic transport characteristics of Na,K-ATPases. 24 As in other systems, SNaK1b likely functions as a chaperone to guide SNaK1a to its correct intracellular location and to modulate enzyme activity.
Both SNaK1a and SNaK1b are expressed in all of the schistosome life stages examined, reflecting the presumed fundamental importance of Na,K-ATPase function in parasite cell biology. Na,K-ATPases generate cationic gradients that are fundamental to a variety of key cellular roles. Since the a-and b-subunits of Na,K-ATPases are both required for proper protein function, it might be anticipated that both subunits should exhibit comparable gene expression profiles. For SNaK1 this is not the case; while both SNaK1a and SNaK1b genes show highest relative expression in the egg stage and comparable expression in the Proteomic analysis detects SNaK1a and SNaK1b in adult worm tegumental membranes 6 suggesting that the dimeric SNaK1 protein functions at the host-parasite interface. In adult parasites, SNaK1a has been immunolocalized to several other tissues including neuronal and muscle tissue suggesting that the protein is of widespread importance. 5 The genes encoding both SNaK1a and SNaK1b can be suppressed by treating parasites with target specific siRNAs. However, SNaK1a suppression following this treatment is consistently greater than SNaK1b suppression. This may reflect differences in target mRNA structure and accessibility to the RNAi machinery. Differences in the suppressibility of different genes have been observed before in schistosomes. 25 As expected from the known key role of Na,K-ATPases in cells, work reported here shows that the SNaK1 protein plays a vital role for schistosomes. Impairing SNaK1 function by suppressing both SNaK1a and SNaK1b genes greatly decreases worm viability in vitro (by about 50%). The importance of SNaK1 for schistosomes is even more apparent from the results of mouse infection experiments. In one experiment, control schistosomula, or schistosomula that were subjected to RNAi targeting both SNaK1a and SNaK1b, were used to infect mice. After 4 weeks, approximately 6 -8 fold fewer SNaK1 suppressed worms were recovered compared to the controls. In addition, the SNaK1targeted worms that were recovered from infected mice tended to be significantly shorter (by about half) when compared to control worms. These results show that targeting SNaK1 severely debilitates schistosomes; parasites that do not die as a result of SNaK1 gene suppression are nonetheless incapacitated and remain stunted compared to their control counterparts. Gene expression comparisons reveal that this population of smaller worms still exhibits some degree of SNaK1 gene suppression; the level of expression of both the SNaK1a gene and the SNaK1b gene in this population of recovered worms remains lower than the level exhibited by either control group. However, in the double-gene suppressed worms recovered from mice, the level of expression of both the SNaK1a gene and the SNaK1b gene had increased, in comparison to equivalent parasites maintained in culture for either 7 days or 23 days. This is a phenomenon reported before: parasites that have had other genes suppressed (e.g. encoding sugar transporter proteins or surface enzymes), when recovered from infected mice, are found to have targeted gene expression levels approaching, or back to, normal. 9, 26 In contrast, suppressed control parasites that are kept in culture, remained suppressed. 9, 26 In additional infection experiments, SNaK1a and SNaK1b double-suppressed schistosomula were maintained in culture for four days prior to infecting mice. The rationale is that culturing parasites in vitro for longer in this manner, prior to infecting mice, may lead to more substantial diminution of target mRNA and protein and therefore yield a clearer manifestation of the importance of the target gene product. This has been explicitly shown for another schistosome mRNA and protein 26 and also seems to be Transactions of the Royal Society of Tropical Medicine and Hygiene the case here, since almost no SNaK1-targeted parasites are recovered when this protocol is followed, while ample control parasites are found. The more devastating outcome for SNaK1 suppressed schistosomes in vivo ( up to 100% dead) compared with those maintained in culture (about 50% dead) indicates that additional pressures are brought to bear on the suppressed parasites in vivo. Parasites debilitated by SNaK1 gene suppression are likely more amenable to immune-mediated killing compared to controls. 16 Given the reported role for Na,K -ATPases in conferring refractoriness to complement-mediated damage of schistosomula, 16 complement-mediated killing of the suppressed parasites may be of foremost importance.
This RNAi work demonstrates unequivocally that schistosomes are very sensitive to perturbation in their SNaK1 levels. We therefore attempted to use these same siRNAs that were used to successfully suppress SNaK1a and SNaK1b gene expression and debilitate worms in vitro to treat an established infection, by delivering these siRNAs to worms within mice. We administered the siRNAs by hydrodynamic injection via the tail vein since this approach has previously been shown to work on schistosomes. 19 Despite the fact that we used 10-fold more siRNA compared to the previous study and we performed two injections compared to one in the previous study, 19 the protocol exerted no overt effect on the parasites; similar numbers of worms were recovered from mice treated with the SNaK1 siRNAs versus control mice. Thus, targeting SNaK1 as described had no observable impact on worm burdens in the mice. In addition, the level of expression of the SNaK1a and SNaK1b genes was not significantly different between the SNaK1-targeted group versus control groups. We conclude that this is because the worms did not take in sufficient siRNA to affect suppression using this method. In the previous siRNA delivery study, 19 worms were treated 10 weeks after infection compared with the 4-week old worms treated here. Perhaps these older worms are more sensitive to RNAi. . Schistosome survival in vivo in mice following treatment with SNaK1a plus SNaK1b siRNAs. One day old schistosomula were treated with none or control siRNA or SNaK1a plus SNaK1b siRNAs (a1 plus b3 siRNAs). Using this protocol, the parasites were cultured in vitro for 4 days before being used to infect mice. Results for three separate experiments (Exp 1-3) are shown. Worm numbers recovered from individual mice in each group after 42 days are shown. The lines indicate the means for each group (in each case, p , 0.01, SNaK1 versus control or none).
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Despite the fact that the delivery of siRNAs targeting SNaK1 did not impact on schistosome infection in mice, it nonetheless seemed likely that a more conventional drug treatment that mimics the RNAi effect should be able to debilitate and kill the parasites. Ouabain is a well-established Na,K-ATPase inhibitory drug that can impact schistosomes; treatment of adult schistosomes with this compound elicits a sizable depolarization of the tegumental cytoplasm and a contraction of somatic muscle. 27 The Na,K-ATPase activity detected in extracts of S. mansoni is sensitive to inhibition by ouabain. 4, 28 Moreover, since the drug has been used clinically in humans for many years 29 -31 successful treatment of schistosomiasis using this drug might augur well for its rapid repositioning for use as a novel anti-parasitic. Therefore, we tested the ability of ouabain administration to clear schistosome infection by delivering the drug weekly to mice that had been infected with 200 cercariae, over 6 weeks at 2.5 mg/kg. This dose was chosen since it approaches the maximum that is well tolerated by mice. 32 While the mice suffered no overt adverse effects of the drug, nor did the schistosomes: equivalent numbers of worms were recovered from the drug-treated versus mock-treated, infected groups. Because of the high relative expression of both SNaK1a and SNaK1b genes in schistosome eggs, as reported in this study, we considered that ouabain treatment might preferentially impact this life stage. Therefore the numbers of eggs deposited in the livers of treated and control mice were compared. Here again, no significant differences were recorded. The inability of ouabain treatment to impact adult worms and worm eggs may be because the parasites were not exposed to a sustained curative dose of the drug. The half-life of ouabain in plasma is about 20 hours. 33 While this drug trial was not successful in curing schistosomiasis in the rodents, other Na,K-ATPase inhibitors exist and, given the sensitivity of the parasites to perturbation in SNaK1 gene expression levels, these may hold promise as novel anthelminthics.
Authors' contributions: AD conducted therapeutic trials targeting SNaK1 and helped draft the manuscript; ZF performed developmental expression analysis and early RNAi work; GKP participated in gene knockdown analysis; RB contributed to the in vivo RNAi studies; PJS conceived of the study, carried out the in silico molecular analysis and drafted the manuscript. PJS is guarantor of the paper. Four weeks after infection with 100 cercariae, mice were treated with the Na,K-ATPase inhibitor ouabain (2.5 mg/kg) every week for 6 weeks.
In the sixth week, mice received two injections, two days apart. One week later, worm burdens were compared in this group versus a control group of infected mice not treated with the drug. Numbers+SD are shown. No significant difference in any parameter was observed between the control versus ouabain-treated group. NA: Not applicable.
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